lenalidomide (REVLIMID°) in untreated multiple myeloma.

Q4 Medicine

Prescrire International Pub Date : 2016-11-01

引用次数: 0

Abstract

In an unblended trial in 1623 multiple myeloma patients, treatment with lenalidomide + dexamethasone until disease progression appeared to prolong survival by a few months more than with the thalidomide + melphalan + prednisone combination given for 18 months, but serious adverse effects were more frequent.

本刊更多论文

来那度胺(REVLIMID°)治疗未经治疗的多发性骨髓瘤。

在一项1623例多发性骨髓瘤患者的非混合试验中，来那度胺+地塞米松治疗直到疾病进展似乎比沙利度胺+美法兰+强的松联合治疗18个月多延长了几个月的生存期，但严重的不良反应更频繁。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊